These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 22682985

  • 21. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer.
    Kaira K, Serizawa M, Koh Y, Takahashi T, Yamaguchi A, Hanaoka H, Oriuchi N, Endo M, Ohde Y, Nakajima T, Yamamoto N.
    Lung Cancer; 2014 Feb; 83(2):197-204. PubMed ID: 24365102
    [Abstract] [Full Text] [Related]

  • 22. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
    Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, Brachmann S, Fritsch C, Dorsch M, Chène P, Shoemaker K, De Pover A, Menezes D, Martiny-Baron G, Fabbro D, Wilson CJ, Schlegel R, Hofmann F, García-Echeverría C, Sellers WR, Voliva CF.
    Mol Cancer Ther; 2012 Feb; 11(2):317-28. PubMed ID: 22188813
    [Abstract] [Full Text] [Related]

  • 23. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS.
    Cancer Res; 2009 Jul 15; 69(14):5835-42. PubMed ID: 19584292
    [Abstract] [Full Text] [Related]

  • 24. Fluorescence imaging of bombesin and transferrin receptor expression is comparable to 18F-FDG PET in early detection of sorafenib-induced changes in tumor metabolism.
    Tseng JC, Narayanan N, Ho G, Groves K, Delaney J, Bao B, Zhang J, Morin J, Kossodo S, Rajopadhye M, Peterson JD.
    PLoS One; 2017 Jul 15; 12(8):e0182689. PubMed ID: 28792505
    [Abstract] [Full Text] [Related]

  • 25. Comparison of [18F]FDG uptake and distribution with hypoxia and proliferation in FaDu human squamous cell carcinoma (hSCC) xenografts after single dose irradiation.
    Bruechner K, Bergmann R, Santiago A, Mosch B, Yaromina A, Hessel F, Hofheinz F, van den Hoff J, Baumann M, Beuthien-Baumann B.
    Int J Radiat Biol; 2009 Sep 15; 85(9):772-80. PubMed ID: 19657862
    [Abstract] [Full Text] [Related]

  • 26. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
    Brünner-Kubath C, Shabbir W, Saferding V, Wagner R, Singer CF, Valent P, Berger W, Marian B, Zielinski CC, Grusch M, Grunt TW.
    Breast Cancer Res Treat; 2011 Sep 15; 129(2):387-400. PubMed ID: 21046231
    [Abstract] [Full Text] [Related]

  • 27. Deciphering PDT-induced inflammatory responses using real-time FDG-PET in a mouse tumour model.
    Cauchon N, Hasséssian HM, Turcotte E, Lecomte R, van Lier JE.
    Photochem Photobiol Sci; 2014 Oct 15; 13(10):1434-43. PubMed ID: 25058054
    [Abstract] [Full Text] [Related]

  • 28. Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma.
    Wei LH, Su H, Hildebrandt IJ, Phelps ME, Czernin J, Weber WA.
    Clin Cancer Res; 2008 Jun 01; 14(11):3416-26. PubMed ID: 18519772
    [Abstract] [Full Text] [Related]

  • 29. Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma.
    Agnihotri S, Gugel I, Remke M, Bornemann A, Pantazis G, Mack SC, Shih D, Singh SK, Sabha N, Taylor MD, Tatagiba M, Zadeh G, Krischek B.
    J Neurosurg; 2014 Dec 01; 121(6):1434-45. PubMed ID: 25245477
    [Abstract] [Full Text] [Related]

  • 30. Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.
    Thézé B, Bernards N, Beynel A, Bouet S, Kuhnast B, Buvat I, Tavitian B, Boisgard R.
    BMC Cancer; 2015 Jul 22; 15():534. PubMed ID: 26198000
    [Abstract] [Full Text] [Related]

  • 31. The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy.
    Hernlund E, Olofsson MH, Fayad W, Fryknäs M, Lesiak-Mieczkowska K, Zhang X, Brnjic S, Schmidt V, D'Arcy P, Sjöblom T, De Milito A, Larsson R, Linder S.
    Eur J Cancer; 2012 Feb 22; 48(3):396-406. PubMed ID: 22154651
    [Abstract] [Full Text] [Related]

  • 32. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
    Baumann P, Mandl-Weber S, Oduncu F, Schmidmaier R.
    Exp Cell Res; 2009 Feb 01; 315(3):485-97. PubMed ID: 19071109
    [Abstract] [Full Text] [Related]

  • 33. Resveratrol suppresses cancer cell glucose uptake by targeting reactive oxygen species-mediated hypoxia-inducible factor-1α activation.
    Jung KH, Lee JH, Thien Quach CH, Paik JY, Oh H, Park JW, Lee EJ, Moon SH, Lee KH.
    J Nucl Med; 2013 Dec 01; 54(12):2161-7. PubMed ID: 24221993
    [Abstract] [Full Text] [Related]

  • 34. 18F-FDG and 18F-FLT Uptake Profiles for Breast Cancer Cell Lines Treated with Targeted PI3K/Akt/mTOR Therapies.
    Dockx Y, Vangestel C, De Bruycker S, Van den Wyngaert T, Huizing M, Staelens S, Stroobants S.
    Cancer Biother Radiopharm; 2023 Feb 01; 38(1):51-61. PubMed ID: 36472460
    [Abstract] [Full Text] [Related]

  • 35. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.
    Oishi T, Itamochi H, Kudoh A, Nonaka M, Kato M, Nishimura M, Oumi N, Sato S, Naniwa J, Sato S, Shimada M, Kigawa J, Harada T.
    Oncol Rep; 2014 Aug 01; 32(2):553-8. PubMed ID: 24927217
    [Abstract] [Full Text] [Related]

  • 36. Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model.
    Matsushima M, Kikuchi E, Matsumoto K, Hattori S, Takeda T, Kosaka T, Miyajima A, Oya M.
    Int J Oncol; 2015 Jul 01; 47(1):377-83. PubMed ID: 25963317
    [Abstract] [Full Text] [Related]

  • 37. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
    Gan ZY, Fitter S, Vandyke K, To LB, Zannettino AC, Martin SK.
    Eur J Haematol; 2015 Apr 01; 94(4):343-54. PubMed ID: 25179233
    [Abstract] [Full Text] [Related]

  • 38. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
    Kim A, Park S, Lee JE, Jang WS, Lee SJ, Kang HJ, Lee SS.
    Leuk Res; 2012 Jul 01; 36(7):912-20. PubMed ID: 22560334
    [Abstract] [Full Text] [Related]

  • 39. Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/FoxO3a signalling in experimental colon cancer.
    Qazi AK, Hussain A, Khan S, Aga MA, Behl A, Ali S, Singh SK, Taneja SC, Shah BA, Saxena AK, Mondhe DM, Hamid A.
    Cancer Lett; 2015 Apr 01; 359(1):47-56. PubMed ID: 25554016
    [Abstract] [Full Text] [Related]

  • 40. Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma.
    Kaira K, Serizawa M, Koh Y, Takahashi T, Hanaoka H, Oriuchi N, Endo M, Kondo H, Nakajima T, Yamamoto N.
    Eur J Cancer; 2012 May 01; 48(8):1244-54. PubMed ID: 22330319
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.